Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Mesothelioma. Found 24 abstracts

no pagination
Tan Y, Sementino E, Chernoff J, Testa JR. Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity. American Journal of Cancer Research. 2017 Aug;7(8):1724-37.   PMCID: PMC5574944
Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer. Cancer Res. 2016 Jan 15;76(2):206-15.   PMCID: PMC4715907
Cheung M, Kadariya Y, Pei J, Talarchek J, Facciolo F, Visca P, Righi L, Cozzi I, Testa JR, Ascoli V. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation. Cancer Genet. 2015 Oct;208(10):502-7.   PMCID: PMC4608746
Deng XB, Xiao L, Wu Y, Jin F, Mossman B, Testa JR, Xiao GH. Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy. International journal of cancer. 2015 Jul 15;137(2):481-90.   PMCID: PMC4428975
Kalra N, Zhang J, Thomas A, Xi L, Cheung M, Talarchek J, Burkett S, Tsokos MG, Chen Y, Raffeld M, Miettinen M, Pastan I, Testa JR, Hassan R. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer. 2015 Jan;15:376.   PMCID: PMC4431029
Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, Xiao GH, Shapiro IM, Kolev VN, Pachter JA, Klein-Szanto AJ, Testa JR. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res. 2014 Feb 15;74(4):1261-71.   PMCID: PMC3945416
Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ, Testa JR. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res. 2014 Aug 15;74(16):4388-97.   PMCID: PMC4165574
Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa JR, Shogen K. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. BMC cancer. 2010 Jan;10:34.   PMCID: PMC2829496
Menges CW, Altomare DA, Testa JR. FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis. Cell cycle (Georgetown, Tex). 2009 Aug 15;8(16):2528-34.   PMCID: PMC2739729
Altomare BA, Testa JR. Cytogenic and molecular genetic changes in malignant mesothelioma. In: O'Byrne K, Rusch VW, editors. Malignant pleural mesothelioma. Oxford: Oxford University Press; 2006. p. 239-50.
Altomare D, Testa JR. Cytogenetic and molecular genetic changes in malignant mesothelioma. O'Byrne K, Rusch VW, editors. Oxford: Oxford University Press; 2006.
Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene. 2006 May;25(44):5960-8.
Cordera F, Scott W. Lymphatic drainage patterns of thoracic malignancies. Journal of Bronchology. 2005 Jan;12(4):254-66.
Baser ME, De Rienzo A, Altomare D, Balsara BR, Hedrick NM, Gutmann DH, Pitts LH, Jackler RK, Testa JR. Neurofibromatosis 2 and malignant mesothelioma. Neurology. 2002 Jul 23;59(2):290-1.
Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002 Feb;29(1):2-17.
De Rienzo A, Tor M, Sterman DH, Aksoy F, Albelda SM, Testa JR. Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey. Journal of cellular biochemistry. 2002 Jan;84(3):455-9.
Apostolou S, Murthy SS, Kolachana P, Jhanwar SC, Testa JR. Absence of post-transcriptional RNA modifications of BCL10 in human malignant mesothelioma and colorectal cancer. Genes Chromosomes Cancer. 2001 Jan;30(1):96-8.
De Rienzo A, Balsara BR, Apostolou S, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene. 2001 Sep 27;20(43):6245-9.
Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001 Jan;7(1):153-7.
Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet (London, England). 2001 Feb 10;357(9254):444-5.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Mesothelioma

Mesothelioma genetics metabolism Human pathology US Gov't Support-PHS Lung Neoplasms Mice Non-US Gov't Support Cultured Tumor Cells Pleural Neoplasms Asbestos Female Male Tumor Suppressor Proteins Mutation Genetic Predisposition to Disease adverse effects physiology Ubiquitin Thiolesterase pharmacology Animal Disease Models Adult Nude Mice Tumor Cell Line Turkey Middle Aged etiology Aged Proto-Oncogene Proteins c-met Simian virus 40 Signal Transduction SCID Mice Phosphorylation Zeolites Neoplasm Invasiveness Oligonucleotide Array Sequence Analysis Chromosome Aberrations drug therapy enzymology virology Pedigree drug effects Cell Survival Germ-Line Mutation Chromosome Disorders Neoplastic Stem Cells Pleural Diseases Neoplasm Transplantation Neurofibromin 2 Asbestos adverse effects Tumor Suppressor Genes Antineoplastic Agents Animal antagonists & Neurofibromatosis 2 Genes Chromosome Mapping Signal Transducing Adaptor Proteins Cancer Fatty Acid Synthetase Complex Immunoenzyme Techniques Antifungal Antibiotics epidemiology Esophagus Western Blotting Population Genetics Middle Age Fatal Outcome Genetic Therapy Genotype RNA toxicity Pak 80 and over Aged Carcinogenesis Tumor Virus Infections Myc Human Chromosomes-Pair 15 mortality Experimental Neoplasms Immunohistochemistry Single-Stranded Conformational Polymorphism p53 Genes beta Catenin Inbreeding Genetic Vectors Fluorescence Microscopy Carrier Proteins Biological Models Occupational Exposure HGF therapy Reverse Transcriptase Polymerase Chain Reaction cancer stem-like cells Cellular Spheroids biosynthesis cytostasis Post-Transcriptional RNA Processing cytology Viral DNA Cultured Cells methods Microsatellite Repeats Neoplastic Gene Expression Regulation Lung Cerulenin HEK293 Cells asbestos Nk4 Sulfones Prognosis US Gov't Support-Non-PHS DNA Mutational Analysis United States immunology Knockout Mice Neurofibromatosis 2 Polymerase Chain Reaction Case Report Fluorescence In Situ Hybridization diagnosis Dominant Genes chemically induced Heterozygote Genetic Models Paraffin Embedding Polymorphism (Genetics) Neoplasm Proteins Point Mutation Cyclin-Dependent Kinase Inhibitor p16 inhibitors Mesothelial Neoplasms Chromosome Deletion Young Adult Malignant mesothelioma Hepatocyte Growth Factor Peritoneal Neoplasms Sequence Deletion Adenoviridae Second Primary Neoplasms Survival Rate therapeutic use antagonists & inhibitors Neoplastic Cell Transformation Bap1 Cell Proliferation Southern Blotting Radiation-Induced Neoplasms Polyomavirus Infections Founder Effect
Last updated on Wednesday, February 05, 2020